Heo Eun-chul, head of GC Biopharma, said in a New Year's address on the 2nd that the company plans to boost competitiveness and drive growth in its domestic and overseas businesses.
Heo first lauded achieving 150 billion won in 2025 sales for "Alyglo," noting the contributions of the U.S. subsidiary, the Global Business Division, the Ochang plant, and the research and development (R&D) institutional sector, and expressed gratitude to employees.
He stressed, "Success in the U.S. market is the result of clear direction-setting, belief in values, and persistence, and now we must expand our influence in the global market not as a supporting actor but as the lead."
He added, "The domestic market, which serves as both the cradle and a forward base for global expansion, must create strong synergy through close communication and support between domestic and global operations to achieve remarkable growth and a leap beyond past glory."
Heo said, "The reason for emphasizing the global business is that it is the only and certain path that promises GC's bright future," adding, "I thank the employees who work tirelessly at all business sites at home and abroad, and let's make this a year of expanding our influence on both the domestic and global stages with one united heart."